Wells Fargo has upgraded CareDx (NASDAQ:CDNA) to equal weight from underweight, citing valuation, but lowered its price ...

CareDx (NASDAQ:CDNA) expects to incur a loss (GAAP) of around $32M to $34M for the fourth quarter of 2024, on revenue of $85M ...

Wells Fargo upgraded Caredx Inc (NASDAQ:CDNA) to "Equal Weight" from "Underweight" given a more balanced risk/reward profile after a roughly 30% decline in the stock since late August, contrasting ...

In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on CareDx (CDNA – Research Report), with a price target of ...

The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.

Hanna, CareDx President and CEO. The preliminary financial information presented in this press release is based on CareDx’s current expectations and may be adjusted as a result of, among other ...

(RTTNews) - CareDx, Inc. (CDNA), Monday reported preliminary loss for the fourth quarter and a 30 percent increase preliminary revenues. For the quarter, the company projects loss to be approximately ...

CareDx (NASDAQ:CDNA) has been analyzed by 3 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

CareDx (NASDAQ:CDNA) expects to incur a loss (GAAP) of around $32M to $34M for the fourth quarter of 2024, on revenue of $85M and $86M (up ~30% year-over-year). Analysts expect Q4 revenue of $82.16M.

CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $82.88 million for the quarter, compared to analysts’ expectations of $80.04 ...

Wells Fargo has upgraded CareDx (NASDAQ:CDNA) to equal weight from underweight, citing valuation, but lowered its price target for the stock. The investment bank said that following a roughly 30% ...